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Breast cancer proliferationAlthough the zinc ﬁnger-homeodomain transcription factor δEF1 is implied as a regulatory factor at the
crossroad between proliferation and differentiation in carcinogenesis, its potential effect in the regulation of
cell cycle progression has not been well elucidated. In our present study, we provide novel ﬁnding that, in
breast cancer, the ectopic expression of δEF1 in MDA-MB-231 cells signiﬁcantly promoted cell proliferation
by increasing the cell number in S phase of the cell cycle. In contrast, δEF1 knockdown by RNA interference
exhibited an opposite effect, highlighting a potent role of δEF1 to promote G1-S transition of breast cancer
cells. Moreover, we demonstrated that δEF1 down-regulated p21 and concurrently up-regulated the
expressions of CDK2 and CDK4 during this process. Further, δEF1 inhibited p21 transcription by recruiting to
the E2 box element on the p21 promoter. Depletion of endogenous δEF1 in MDA-MB-231 cells was sufﬁcient
to allow an inherent release of p21 expression, thus resulting in the cell cycle arrest. In addition, the
stimulatory effect of δEF1 on cell proliferation through p21 regulation was supported by an inverse
correlation of δEF1 and p21 expressions observed in both breast cancer cell lines and clinical tumor
specimens. Taken together, these observations suggest a dual effect of δEF1 in promoting breast cancer cell
proliferation, by differentially regulating the cell cycle regulatory proteins.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Breast cancer cell progression is a coordinated process that
comprises cell cycle dysregulation and a speciﬁc gene expression
program to determine tissue identity. Many studies have provided
knowledge about the molecules involved in cell proliferation and key
regulatory transcription factors that control tissue speciﬁc gene
expression [1,2]. At different phases, progression through cell cycle
is regulated by sequential activation and subsequent inactivation of a
series of cyclin-dependent kinases (CDKs), whose activity depends on
interactions with timely expressed cyclins and cyclin-dependent
kinase inhibitors (CDKIs) [3-5]. For instance, the transition from G1 to
S phase requires the activation of two classes of CDKs, CDK4/6 and
CDK2. As cells emerge from quiescence in response to mitogenic
stimuli, D type cyclins are synthesized and associatewith CDK4/6. The
cyclin D-CDK4/6 complex hyperphosphorylates retinoblastoma pro-
tein (RB), leading to its release from transcription factor E2F. The freed
transcription factor E2F would then activate the genes responsible forat Medical College of Nankai
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ll rights reserved.cellular proliferation including cyclin E. Cyclin E binds to and activates
CDK2 kinase contributing to G1-S phase progression [6-8]. Among the
CDKIs, p16INK4A (p16), a member of the INK4 protein family, is
speciﬁcally induced at the end of the G1 phase in response to pRB
phosphorylation as a retrocontrol mechanism to inhibit CDK4/6. In
addition, p21Cip1/WAF1 (p21) and p27Kip1 (p27), members of the Cip/
Kip family, inhibit a broad range of CDKs, including CDK4/6 and CDK2
[9-11]. Given that decreased expression of p21 is associated with the
promotion of tumor formation and a poor prognosis in many types of
cancer [11,12], it is of signiﬁcance to characterize the mechanisms
underlying the transcriptional regulation of p21 gene, for an
understanding of the genesis of cancers and for a search of novel
therapeutic target for cancer [13,14].
Recent reports provided evidence that the zinc ﬁnger-home-
odomain transcription factor δEF1 regulates gene expression to
modulate cell differentiation and tissue-speciﬁc functions [15-21].
Presence of δEF1 has been implicated in the inhibition of differenti-
ation of multiple cell lineages including muscle [17], cartilage [18],
bone [19,20], and neural cells [21]. Further studies revealed that δEF1
is also involved in the epithelial–mesenchymal transition (EMT) that
takes place concomitant with the acquisition of progressive properties
in tumors [22-27]. δEF1 is expressed in invasive cells of various
tumors, including lung [22], squamous [23], uterine [24], and breast
cancers [25-27]. δEF1 appears to be an early marker of malignant
phenotype as well as a prognostic factor [28]. In addition, δEF1 is
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by its role in repressing p73 expression [29-31]. δEF1 could indeed act
as a primary survival factor and inducer of cell movement, apart from
its role in EMT. Notwithstanding, a direct role for δEF1 in cell
proliferation and its relation with EMT or other δEF1-associated
functions is yet to be established.
To address this issue, we have performed studies on the gain or
loss of function of δEF1 in the highly undifferentiated human breast
carcinoma MDA-MB-231 cell line. Flow cytometry assays after BrdU
incorporation present evidence that δEF1 overexpression promoted
cell cycle progression by increasing cell number in the S phase,
whereas δEF1 knockdown exhibited an opposite effect. Importantly,
to control breast cancer cell proliferation, δEF1 down-regulated p21
and concurrently up-regulated the expressions of CDK2 and CDK4.
These data collectively suggest a signiﬁcant role of δEF1 in breast
cancer tumor growth and metastasis.
2. Materials and methods
2.1. Tissue samples
Fresh breast cancer tissues of invasive ductal carcinoma were
obtained from the Tissue Banking Facility Jointly Supported by
TMUCIH (Tianjin Medical University Cancer Institute and Hospital)
& NFCR (National Foundation for Cancer Research). Tissue samples
were stored at−70 °C until being used in the assay. All patients were
histologically conﬁrmed as having breast cancers and were recruited
in the same department. The study was approved by the institutional
ethics committee.
2.2. Cell culture
MDA-MB-231, MCF-7, T47D, and ZR-75-1 cells were maintained in
DMEM-high glucose medium (GIBCO) supplemented with 10% FBS
(Hyclone), penicillin, and streptomycin.MDA-MB-231 cells were plated
at a density of 8×104 cells/well in 6-well plates for quantitative CHIP
andwesternblotting assays.MDA-MB-231 cellswere plated at a density
of 2×104 cells/well in 24-well plates for use in luciferase assays.
2.3. Plasmids construction and transfection
The generation of full-length δEF1 expression vector (pcDNA6B-δ-
FL) has been previously described [19]. Human p21 promoter
sequence (−557/+19) was obtained by PCR from human blood
genomic DNA and cloned into the pGL3-basic vector (Promega) using
the forward primer, 5′-GCTGAGCTCGTCTAGGTGCTCCAGGTGC-3′, and
reverse primer, 5′-GCAGATCTCGAGGAACTGAC-3′. Mutagenesis of the
E2 box in the human p21 promoter was performed using the
QuickChange Site-Directed Mutagenesis Kit (Stratagene) with the
forward primer: 5′-gtctaggtgctcCAGATGcttctgggagagg -3′ and reverse
primer: 5′-cctctcccagaagCATCTGgagcacctagac-3′.
MDA-MB-231 cells were plated in a 10-cm dish andwere grown to
conﬂuent. 2×107 cells were collected and washed twice with PBS,
electroporated at 360 V, 950 uF using a Gene Pulser II System (Bio-
Rad). Transfected cells were resuspended in 2 ml of DMEM medium
containing 10% FBS and seeded in a 6-well plate. Transient
transfection with pcDNA6B-δ-FL was performed with electroporation
inMDA-MB-231 cells. Blasticidin-resistant clones were isolated over a
period of 3–4 weeks. Overexpression of δEF1 was conﬁrmed by
western immunoblot analysis.
2.4. Cell proliferation assay
MDA-MB-231 cells stably transfected with pcDNA6B-δ-FL or
pcDNA6B vector control were plated in a 96-well plate at a
concentration of 5×103 cells/well. At the indicated time point, thecell proliferation assay was performed by the addition of 10 μl CCK-
8 (Cell Counting Kit-8, Jindojin) solution to each well, followed by
incubation at 37 °C for 2 h. Absorbance was measured at a wavelength
at 450 nm using a microplate reader.
2.5. BrdU incorporation and ﬂow cytometry
To evaluate proliferation, 5-bromo-2′-deoxyuridine (BrdU) incor-
poration was examined. MDA-MB-231 cells transiently transfected
with pcDNA6B-δ-FL or pcDNA6B vector control were seeded onto 10-
cm plates with a conﬂuence level from 50% to 70%. Cells were
incubated for 60 min with 10 μM BrdU at 0, 24, 48, and 72 h after
transfection. After the 60-min pulse, the cells were washed twice with
PBS, removed from the plates, centrifuged at 500×g for 5 min, and
ﬁxed with ice-cold 70% ethanol. Fixed cells proceeded for DNA
fragment detection were washed with PBS, resuspended in 2 M HCl
containing 0.5% (v/v) Triton X-100, and incubated at RT for 30 min.
Cells were subsequently centrifuged and resuspended in 0.1 M
Na2B4O7 (pH 8.5) for 2 min. After a repeat centrifugation, cell pellets
were resuspended in washing solution (PBS containing 0.5% (v/v)
Tween 20 and 1% (w/v) BSA). The cells were spun down, and mouse
monoclonal Ab against BrdU (sc-32323, Santa Cruz) diluted 1:100 in
washing solution was added. The cells were incubated in the dark for
1 h at RT, washed and resuspendedwithwashing solution. Alexa Fluor
488 goat anti-mouse IgG Ab (Invitrogen) diluted to a predetermined
working concentration of 100-fold was added. After 1 h incubation at
RT, cells were washed and resuspended in PBS. For nuclear staining
with propidium iodide, the cells were treated with 50 μl RNase A
(1 mg/ml) (Sigma) followed by 100 μl propidium iodide (100 μg/ml).
Dual parameter measurements of green-versus-red ﬂuorescence
signals were taken by a ﬂow cytometry on FACcalibur (BD) equipped
with argon laser excitation (power 200mW) at 488 nm, a 510- to 540-
nm interference ﬁlter for the detection of FITC green ﬂuorescence, and
a 610-nm long-pass ﬁlter for the detection of PI red ﬂuorescence. At
least 2×104 cells/sample were measured and subsequently analyzed
by MODFIT software.
2.6. RNA extraction and quantitative RT-PCR
Total RNA was extracted from MDA-MB-231, MCF-7, T47D, and
ZR-75-1 cells using the TRIzol Reagent (Invitrogen). 0.5 μg of the total
RNA from each sample was used for ﬁrst strand cDNA synthesis (M-
MLV Reverse Transcriptase, Promega). Speciﬁc transcripts of human
CDK2, CDK4, CDK6, and human p21 were ampliﬁed by quantitative
PCR using the following primers: CDK2, 5′-GTCCCCAGAGTCCGAAA-
GAT-3′ (forward), and 5′-GCTTTCTGCCATTCTCATCG-3′ (reverse);
CDK4, 5′-ACGGGTGTAAGTGCCATCTG-3′ (forward), and 5′-
TGGTGTCGGTGCCTATGGGA-3′ (reverse); CDK6, 5′-CCACTGAGGTTA-
GAGCCATC-3′ (forward), and 5′-CGAATGCGTGGCGGAGATC-3′
(reverse); p21, 5′-GCGGAACAAGGAGTCAGA-3′ (forward), and 5′-
GGAGAAACGGGAACCAG-3′ (reverse). GAPDHwas used as an internal
control. Veriﬁcation of the expression levels of genes was performed
by quantitative RT-PCR using EvaGreen (Botium). The expression
level was expressed as the threshold cycle (CT) values of the target
and reference gene-GAPDH, which is constitutively expressed.
Comparison and calculation of CT values was used to determine the
relative mRNA levels expressed as the fold change of target genes
relative to the reference gene.
2.7. Western immunoblot analysis and antibodies
Preparation of total cell extracts andwestern blotting analysis with
the appropriate antibodies was performed as described [19]. The
following antibodies (Abs) were used: goat polyclonal Ab against the
N-terminal epitope of δEF1 (ZEB-E20, Santa Cruz); rabbit polyclonal
Ab against CDK2 (sc-163, Santa Cruz); rabbit polyclonal Ab against
303F. Hu et al. / Biochimica et Biophysica Acta 1802 (2010) 301–312CDK4 (sc-260, Santa Cruz); mouse monoclonal Ab against p21 (sc-
6246, Santa Cruz); mouse monoclonal Ab against p27 (sc-56454,
Santa Cruz); mouse monoclonal Ab against Actin (A-4700, Sigma).
2.8. Preparation of small interfering RNAs
The target sequence of the siRNA for human δEF1 is 5′-
TGATCAGCCTCAATCTGCA-3′ as previously reported [25]. Sense and
antisense oligonucleotides with the internal loop were synthesized
(TaKaRa). These were annealed and ligated into the BamHI and
HindIII sites of pSilencer 4.1-CMVneo (Ambion) to construct the
δEF1-speciﬁc and the BMP-6-speciﬁc siRNA expression plasmids,
respectively, according to the manufacturer's instructions. pSilencer
4.1-CMVneo expressing scrambled siRNAs (Ambion) were used as
controls. Transient transfection with siRNAs was performed with
electroporation in MDA-MB-231 cells. G418-resistant clones were
isolated over a period of 3–4 weeks. Down-regulation of δEF1 was
conﬁrmed by western immunoblot analysis.
2.9. Luciferase assay
MDA-MB-231 cells were transfected with wild-type or mutant
human p21 promoter constructs in 24-well plates using
Lipofectamine 2000 (Invitrogen). Lysates were prepared 24 h after
transfection. The luciferase activity was then measured using the
Dual-Luciferase Reporter Assay System (Promega) according to the
manufacturer's instructions. Luciferase activity was normalized using
the Renilla luciferase activity.
2.10. Chromatin immunoprecipitation (CHIP) and quantitative CHIP
assays
ChIP assays were performed using reagents commercially obtained
fromUpstate, essentially according to themanufacturer's instructions.
The antibodies (10 μg) used in these experiments were rabbit
polyclonal antibody against the N-terminal epitope of δEF1 (ZEB-
E20, Santa Cruz), anti-FLAG M2 antibody (F3165, Sigma), and anti-
mouse normal IgG (sc-2025, Santa Cruz). The amount of each speciﬁc
DNA fragment in immunoprecipitates was determined by PCR or
quantitative PCR reactions. The fragment of human p21 promoter,
containing the E2 box, was PCR-ampliﬁed using the following primers:
5′-TAAACGGGACTGAAAA-3′ (forward), and 5′-GAAAAGCCCCACAAT-
3′ (reverse). For quantitative CHIP, a standard curvewas generated for
p21 promoter using the following primers: 5′-TGTGAGGTAGATGG-
GAGC-3′ (forward), and 5′-CAGATCATGCAGCAAAGA-3′ (reverse).
Copy numbers for the DNA fragments −577/−449 bp of p21
promoter in each anti-ZEB-immunoprecipitated sample were deter-
mined and compared to copy numbers of the DNA fragment without
IP (input DNA). Anti-FLAG antibody was used as controls for IP
reactions. The percentage of the input was then calculated. The ﬁnal
value was the percentage of the DNA input obtained from speciﬁc
antibody-IP samples subtracting the percentage of DNA input
obtained from control antibody-IP samples. The dissociation curve
was determined for each quantitative PCR reaction to assure that a
single band was produced. Each data point represents three
independent samples.
3. Results
3.1. δEF1 overexpression promotes the proliferation of MDA-MB-231
breast cancer cells
We previously reported that δEF1 overexpression stimulates the
proliferation of murine pre-myoblast C2C12 cells, which effect is
independent of BMP-2 activity [19]. In the present study, we assessed
the effect of δEF1 in regulating cell cycle progression of breast cancerusing cell proliferation assay. MDA-MB-231 breast cancer cells were
stably transfected with full-length δEF1 expression plasmid or a siRNA
plasmid targeting δEF1. Overexpression or knockdown of δEF1 was
conﬁrmed by western blotting (Fig. 1A and B). As seen in Fig. 1C, in
δEF1-overexpressing cells, cell number increased signiﬁcantly after
24 h, in comparison to the empty vector transfected cells. In contrast,
depletion of δEF1 in MDA-MB-231 cells exhibited a decreased
proliferative rate, compared to the control cells (Fig. 1C), indicating
a promoting effect of δEF1 on proliferation of MDA-MB-231 cells.
Furthermore, ﬂow cytometricmeasurements after BrdU incorporation
conﬁrmed an increase in the number of cells in the S phase after δEF1
overexpression in MDA-MB-231 cells. Full-length δEF1 expression
plasmid or the empty vector control was respectively introduced
into MDA-MB-231 cells. At 24 h after transfection, the percentage of
cells in the S phase of δEF1-overexpressing sample was 70.8±1.2%,
while that of the control was 61.4±0.9% (Fig. 1D). At 48 h, the
cell percentage in the S phase of δEF1-overexpressing sample was
58.5±0.7%, compared to that of the control which was 50.7±0.4%
(Fig. 1D). Based on this, we hypothesized that knockdown of δEF1
using RNA interference would result in a decrease of cell number in
the S phase. To do so, a siRNA expression plasmid targeting δEF1 or a
scrambled control siRNA plasmid was transiently transfected into
MDA-MB-231 cells. The knockdown of δEF1 expression was shown by
western blotting (Fig. 1E). As shown in Fig. 1E, at 24 h after
transfection, the cell number in the S phase of δEF1-interfered sample
was 33.0±1.0%, while that of the control was 46.6±0.8%. At 48 h, the
percentage of cells in the S phase of δEF1-interfered sample was
42.3±1.3%, compared to that of the control which was 48.0±1.4%
(Fig. 1E). Taken together, these data suggest that δEF1 signiﬁcantly
promotes cell cycle progression of S phase in MDA-MB-231 cells.
3.2. δEF1 controls MDA-MB-231 cell proliferation by concurrently
down-regulating p21 and up-regulating CDK2 and CDK4
To understand the molecular changes, we performed the quanti-
tative RT-PCR to examine the effect of δEF1 on the CDK inhibitors p21
and p27 involved in the G1-S transition. As shown in Fig. 2A, p21
mRNA level was signiﬁcantly down-regulated after δEF1 overexpres-
sion. δEF1 transfection for 3 h resulted in an up to 40% decrease in the
expression of p21 mRNA, compared to the basal level (Fig. 2A). The
inhibition was further down to about 70% between 6 and 24 h (Fig.
2A). At the protein level, δEF1 transfection resulted in an up to 60%
decrease in the expression of p21 protein as early as 12 h, compared to
the empty vector control. In 24 h, repression of p21 expression by
δEF1 became milder and was maintained at about 20% (Fig. 2B). In
contrast, depletion of δEF1 exhibited a marked up-regulation (up to
3.8-fold relative to that of the control at 24 h) in themRNA level of p21
in MDA-MB-231 cells (Fig. 2C). However, the expression of p27 was
not signiﬁcantly affected by δEF1 overexpression (Fig. 2B). These
observations indicated that down-regulation of p21 occurred at the
transcriptional level and was speciﬁcally mediated by δEF1, contrib-
uting to the promotion of breast cancer cell proliferation.
We further moved on to assess the potential effect of δEF1 on cell
cycle regulatory protein CDKs, including CDK2, CDK4 and CDK6
involved in the G1-S transition. Full-length δEF1 expression plasmid
was transiently transfected into MDA-MB-231 cells. Total RNAs were
collected at 0, 24, 48, and 72 h following each transfection. The results
of quantitative RT-PCR showed that δEF1 overexpression up-regulat-
ed the mRNA levels of CDK2 and CDK4 in a time-dependent manner.
δEF1 overexpression resulted in an up to 1.8-fold increase in the
expression of CDK2 mRNA at 3 h, compared to the basal level. In
addition, δEF1 transfection for 6–12 h also showed an induction to 3–
3.5-fold in the expression of CDK4mRNA (Fig. 3A). On the other hand,
depletion of δEF1 expression in MDA-MB-231 cells resulted in a
decreased mRNA level of CDK2 and CDK4, compared to the control
cells (Fig. 3B). CDK6mRNA level was not as affected (data not shown).
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CDK4 protein levels were markedly up-regulated by δEF1 transfection
at 12–24 h. The above observations suggested a dual effect of δEF1 in
promoting MDA-MB-231 cell proliferation, through concurrently
down-regulating p21 and up-regulating CDK2 and CDK4.
3.3. δEF1 represses the transcriptional activity of p21 promoter by
binding to the E2 box (CAGGTG) element
Having found that δEF1 inhibited p21 expression in MDA-MB-231
cells, we were curious about whether δEF1 is a bona ﬁde repressor
of p21 transcription. As shown in Fig. 4B, a reporter gene assay
showed that δEF1 overexpression signiﬁcantly repressed human p21
promoter activity of the wild-type −557/+19 reporter gene. The
repression was about 50% relative to the control without δEF1
transfection. Meanwhile, we found that δEF1 regulated the promoter
activity of p21 in a dose-dependent manner (Fig. 4C), conﬁrming a
role of δEF1 in the negative regulation of p21 transcription.
δEF1 has been reported to function as a transcriptional repressor
by directly binding to the E2 box [CA(C/G)(C/G)TG] in the promoter
region of target genes with its zinc ﬁnger clusters which are located
close to the N and C termini of the molecule [32,33]. In this present
report, a search using the transcription factor database TESS identiﬁed
an E2 box (CAGGTG) that is located at position−545/−540 of human
p21 promoter. In order to investigate whether δEF1 regulates the
transcriptional activity of human p21 promoter through this putative
response element, a truncated p21 promoter reporter p21-tE2 was
constructed (Fig. 4A). The results showed that, by E2 box depletion,
p21-tE2 exhibited an increased luciferase activity relative to the
−557/+19 promoter p21-wt (Fig. 4B). Further, δEF1-inducedFig. 1. δEF1 overexpression promotes the proliferation of MDA-MB-231 breast cancer cells. (
control (Δ6B) and δEF1-overexpressing (ΔδEF1) MDA-MB-231 cells. Actin was used as a loa
MB-231 cells. Control cells were treated with a scrambled siRNA. The efﬁciency of δEF1 prote
used as a loading control. (C) δEF1 or si-δEF1 stable transfectants in MDA-MB-231 cells w
generated by daily measurements of the cell number of each group. ⁎pb0.05 in unpaired Stu
transfected with δEF1 or empty-vector control. At the indicated time points (0, 24, 48, and 7
assay. The upper panel represents the controls of BrdU−/PI−, BrdU+/PI−, and BrdU−/PI
siRNA plasmid (siRNA-δEF1) or a scrambled siRNA control. The efﬁciency of δEF1 protein kno
as a loading control. At the indicated time points (0, 24, and 48 h), cell proliferation assaystransrepression of p21-tE2 was blunted (by ∼20%) compared to the
control without δEF1 transfection (Fig. 4B), indicating that deletion of
the E2 box on human p21 promoter signiﬁcantly attenuated the
repressive effect of p21 transcription by δEF1. In addition, the E2 box
on human p21 promoter was mutated to generate the p21-mE2
construct as shown in Fig. 4A. Luciferase assay showed that E2 box
mutation also resulted in an increase of the luciferase activity of p21-
mE2, in comparison to the p21-wt promoter (Fig. 4B). Similarly, the
repression of p21-mE2 promoter activity by δEF1 was markedly
weakened (Fig. 4B). These data conﬁrmed that δEF1 inhibited the
transcription of p21 through engaging the E2 box on the p21
promoter.
We further hypothesized that knockdown of δEF1 using RNA
interference would result in an activation of the p21 promoter. To do
so, a siRNA expression plasmid targeting δEF1 or a scrambled control
siRNA plasmid was co-transfected with the p21 promoter reporter
into the MDA-MB-231 cells. The knockdown of δEF1 mRNA expres-
sion was conﬁrmed by RT-PCR (Fig. 4D). The results showed that δEF1
depletion resulted in a signiﬁcant increase in the promoter activity of
p21, compared to the cells transfected with the control (Fig. 4D).
Therefore, the down-regulation of endogenous δEF1 in breast cancer
cells is sufﬁcient to allow an inherent release of p21 expression.
In order to determine whether endogenous δEF1 binding to the
human p21 promoter is mediated through the E2 box element, we
performed quantitative CHIP assays. Speciﬁcally, total protein lysates
fromMDA-MB-231 cells were incubated with an anti-ZEB antibody in
order to precipitate the endogenous δEF1. As shown in Fig. 5A, δEF1
bound to the p21 promoter at the basal state in an E2-box-dependent
manner. δEF1 transfection increased its binding to the endogenous
p21 promoter by 2.2 folds, compared to the control (Fig. 5B). The dataA) Western blotting with anti-ZEB antibody was performed to show δEF1 expression in
ding control. (B) δEF1-speciﬁc siRNA plasmid (siRNA-δEF1) was introduced into MDA-
in knockdownwas examined by western blotting, using an anti-ZEB antibody. Actin was
ere cultured in regular growth medium for 4 days, respectively. A growth curve was
dent t test when compared with vector alone. (D) MDA-MB-231 cells were transiently
2 h), cell proliferation assays were done with BrdU incorporation using ﬂow cytometry
+, respectively. (E) MDA-MB-231 cells were transiently transfected with δEF1-speciﬁc
ckdown was examined by western blotting, using an anti-ZEB antibody. Actin was used
were done with BrdU incorporation using ﬂow cytometry assay.
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Fig. 2. δEF1 down-regulates p21 expression while promoting cell proliferation of MDA-MB-231 cells. (A) δEF1-induced down-regulation of p21 mRNA in MDA-MB-231 cells was
veriﬁed by quantitative RT-PCR. GAPDHwas used to normalize the p21 level. Data represent three independent experiments. (B) δEF1-regulated expressions of p21 and p27 proteins
in MDA-MB-231 cells were veriﬁed by western blotting. Actin was used to normalize the p21 and p27 levels. (C) δEF1-speciﬁc siRNA plasmid (si-δEF1) was introduced into MDA-
MB-231 cells using transient transfection. Control cells were treated with a scrambled siRNA. The efﬁciency of δEF1 mRNA knockdown was examined by RT-PCR. The inhibition of
p21 mRNA level was determined at different time points (0, 24, and 48 h) after transfection, using quantitative RT-PCR. GAPDH was used to normalize the p21 level. SIP1, a close
homolog of δEF1, was used as an off-set control of siRNA interference. Data represent three independent experiments.
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recruitment to the p21 promoter.
3.4. Expression levels of δEF1 and p21 are inversely correlated in
breast cancer
Loss of p21 expression has been reported to predict aggressive
behavior in several cancer malignancies, including breast cancer
[12,34]. To test whether δEF1 mediates the transcriptional repres-
sion of p21 in human tumor cells, we ﬁrst performed quantitative
RT-PCR to examine the expressions of δEF1 and p21 in a panel of 4
human breast cancer cell lines. Interestingly, MDA-MB-231 cellsthat expressed high levels of δEF1 exhibited very low of p21
transcripts (Fig. 6A). Conversely, the p21-positive cells had strongly
reduced δEF1 mRNA levels, as shown in MCF-7, T47D, and ZR-75-1
cells (Fig. 6A). Similarly, the inverse correlation of δEF1 and p21
expressions in these cell lines was also shown by western blotting
(Fig. 6A).
We are further interested in the relationship between δEF1 and
p21 in human breast cancer tissue samples. We collected 22 pairs
(cancer and paracancer) of matched advanced breast tumor speci-
mens of invasive ductal carcinoma, among which two cancers (9%)
had low (I) histological grade (T1 and T2), 16 cancers (73%) had
intermediate (II) grade (T3 to T18), and four cancers (18%) had high
Fig. 3. δEF1 concurrently up-regulates the expressions of CDK2 and CDK4 while promoting cell proliferation of MDA-MB-231 cells. (A) δEF1-induced up-regulation of CDK2 and CDK4
mRNA levels in MDA-MB-231 cells were veriﬁed by quantitative RT-PCR. GAPDH was used to normalize the CDK2 and CDK4 levels. Data represent three independent experiments. (B)
δEF1-speciﬁc siRNAplasmid (si-δEF1)was introduced intoMDA-MB-231 cells using transient transfection. Control cellswere treatedwith a scrambled siRNA. The efﬁciency of δEF1mRNA
knockdownwas examined by RT-PCR. The inhibition of CDK2 and CDK4mRNA levels were determined at different time points (0, 24, and 48 h) after transfection, using quantitative RT-
PCR. GAPDHwas used to normalize the CKD2 and CDK4 levels. SIP1was used as an off-set control of siRNA interference. Data represent three independent experiments. (C) δEF1-induced
up-regulation of CDK2 and CDK4 protein levels in MDA-MB-231 cells was veriﬁed by western blotting. Actin was used to normalize the CDK2 and CDK4 levels.
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Fig. 4. δEF1 represses the transcriptional activity of p21 promoter by binding to E2 box. (A) Sequential deletion andmutation of the human p21 promoter were fused to the luciferase
reporter. (B) MDA-MB-231 cells on 24-well plate were co-transfected with the δEF1 expression plasmid (1 μg/well) and wild-type (p21-wt), or truncated (p21-tE2), or mutated
(p21-mE2) p21 promoter luciferase reporters (1 μg/well), respectively. The luciferase activity of the extracts was determined 24 h after transfection using a Betascope analyzer.
Luciferase values are normalized with Renilla activities. ⁎pb0.05 in unpaired Student t test when compared with vector alone. Data represent three independent experiments. (C)
MDA-MB-231 cells on 24-well plate were co-transfected with different amount of δEF1 expression plasmid (0, 0.5, 1, or 2 μg/well) and wild-type (p21-wt) p21 promoter luciferase
reporter (1 μg/well). The luciferase activity of the extracts was determined 24 h after transfection using a Betascope analyzer. Luciferase values are normalized with Renilla activities.
⁎pb0.05 in unpaired student t test when compared with vector alone. ⁎⁎pb0.05 in one-way analysis of variance followed by Dunnett's test when compared with vector alone. Data
represent three independent experiments. (D) δEF1-speciﬁc siRNA plasmid (si-δEF1) and wild-type (p21-wt) p21 promoter luciferase reporter were co-transfected into MDA-MB-
231 cells. The inhibition of δEF1 mRNA level was determined at different time points (0, 24, and 48 h) after transfection, using RT-PCR. SIP1 was used as an off-set control of siRNA
interference. The luciferase activity of the extracts was determined 24 and 48 h after transfection using a Betascope analyzer. Luciferase values are normalized with Renilla activities.
⁎pb0.05 in unpaired Student t test when compared with vector alone. ⁎⁎pb0.05 in one-way analysis of variance followed by Dunnett's test when compared with vector alone. Data
represent three independent experiments.
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correlation between δEF1 and p21was clearly evident in T1, T3, T4, T7,
T8, T10-14, T17, T18, T20, T22 (14 out of 22 tissue samples).Moreover,
we found that δEF1 expression was much higher in tumor tissue than
that in the corresponding normal tissues, whereas p21 expression
level was higher in normal tissues (Fig. 6C). Together, these data
suggest a strong inverse relationship between the expressions of δEF1and p21, which may contribute to the invasive and metastatic
capacities of breast cancer cells.
4. Discussion
Breast carcinogenesis is the result of cell cycle disorganization,
leading to an uncontrolled cellular proliferation. Speciﬁc cellular
Fig. 5. δEF1 overexpression increases its recruitment to endogenous p21 promoter in an E2-box-dependent manner. (A) Association of δEF1 with the proximal human p21 promoter
was analyzed by CHIP analyses in MDA-MB-231 cells, using polyclonal antibody against δEF1 or unrelated IgG antibody. Ampliﬁed human p21 promoter fragment of E2 box
containing sequence is shown. Amount of DNA in input conﬁrms equal loading of chromatin. (B) δEF1 transfection to MDA-MB-231 cells signiﬁcantly enhanced its recruitment to
endogenous p21 promoter by quantitative CHIP assay. ⁎pb0.05 in unpaired Student t test when compared with vector alone. Data represent three independent experiments.
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point traversation through the intermitotic phases are deregulated.
We previously uncovered that one of the zinc ﬁnger-homeodomainFig. 6. Expressions of δEF1 and p21 are inversely correlated in breast cancer. (A) mRNA and p
cells were detected by quantitative RT-PCR and western blotting, respectively. GAPDH and a
two genes were determined in tumor samples from 22 breast cancer specimens by quan
Transcript levels of the two genes were determined in the tumor tissues (T) and the correspo
is much higher in the tumor tissues than that in the corresponding normal tissues. Oppositely
p21 in normal breast tissue was normalized to 1.transcription factors, δEF1, might contribute to the regulation of cell
cycle progression in C2C12 cells. The current study was designed to
investigate the mechanism by which δEF1 promotes cell proliferationrotein levels of δEF1 and p21 in MDA-MB-231, MCF-7, T47D, and ZR-75-1 breast cancer
ctin were used to normalize the individual expression levels. (B) Transcript levels of the
titative RT-PCR. GAPDH was used to normalize the individual expression levels. (C)
nding normal tissues (N), respectively, using quantitative RT-PCR. δEF1 expression level
, p21 expression level exhibited higher in normal tissues. The expression level of δEF1 or
311F. Hu et al. / Biochimica et Biophysica Acta 1802 (2010) 301–312in breast cancer. Our results show that δEF1 signiﬁcantly promotes cell
cycle progression by increasing the cell number in the S phase inMDA-
MB-231 cells. During this process, δEF1 speciﬁcally down-regulates
p21 transcription by binding to the E2 box (CAGGTG) on its promoter.
Moreover, the inverse correlation of δEF1 and p21 expressions is
present in both breast cancer cell lines and in the clinical tumor
specimens. Our observations provide the novel evidence, at the
cellular and molecular levels, that δEF1 controls proliferation by
regulating cell cycle regulatory proteins, such as p21, CDK2, and CDK4,
in breast cancer progression.
Recent evidences support δEF1 as a potential regulatory factor at
the crossroad between proliferation and differentiation in various
cells. p73, a new p53 homolog, has been well deﬁned to be closely
related to growth arrest, apoptosis, and differentiation [29,35,36].
Fontemaggi et al. reported the binding of δEF1 to speciﬁc E boxes
within the ﬁrst intron of the p73 gene, and that implies that p73 is a
speciﬁc target for transcriptional repression by δEF1 during muscle
and neuronal differentiation [29]. They further demonstrated a
distinct pattern of in vivo recruitment of δEF1 to p73 regulatory
regions is found between proliferating and differentiating muscle
cells, suggesting a role of δEF1 as a survival factor and inducer of cell
movement [30]. These previous observations are consistent with our
results that δEF1 stimulates proliferation of pre-myoblast C2C12 cells
and concurrently inhibits BMP-2-induced cell differentiation, an effect
that is not mediated via the canonical BMP/Smad signaling pathway,
but instead by differential regulation of the AP-1 pathway [19]. These
raised a critical and intriguing issue with regard to whether δEF1 may
trigger mutually exclusive cellular effects on tumor cells, i.e. regulated
cell cycle versus deregulated cell proliferation leading to tumor
progression. It has been known that EMT describes the differentiation
switch between polarized epithelial cells and contractile and motile
mesenchymal cells, and facilitates cell movements during carcino-
genesis [37,38]. A growing body of evidence have strongly indicated a
signiﬁcant role of δEF1 in the regulation of EMT progression in a
variety of carcinomas, including breast cancer [22-27,39]. Previous
research from our group demonstrated that δEF1 overexpression
represses BMP-6-induced up-regulation of E-cadherin in MDA-MB-
231 cells, thus inducing breast cancer EMT [26]. Importantly, a dual
mechanism for BMP-6-regulated δEF1 expression is elucidated,
involving cross-talks between AP-1-mediated transcriptional repres-
sion and micoRNA-192-mediated translational inhibition [39]. How-
ever, the proliferative nature of breast cancer regulated by δEF1 has
not been recognized yet. In the present study, we provided novel
evidence that δEF1 overexpression signiﬁcantly promotes cell cycle
progression by increasing the cell number in the S phase in MDA-MB-
231 cells. On the other hand, RNA interference targeting δEF1
exhibited an opposite effect to inhibit G1-S transition of the cell
cycle, conﬁrming a potential role of δEF1 in the regulation of cell
proliferation. Taken together, these ﬁndings strongly suggest a
possible mechanism that simultaneous growth promotion and
migration of tumor cell may occur during metastasis.
Several studies described p21 as a potent regulator of cell
proliferation in various cell culture models [40]. For instance, in NIH
3T3 cells, hepatitis C virus (HCV) core protein represses the p21
promoter through the TGF-β-responsive element (TβRE), suggesting
that HCV core protein stimulates cell cycle progression by repressing
p21 transcription through inhibition of a TGF-β pathway [41].
Similarly, the AP-1 transcription factor c-Jun, a key inducer of
hepatocyte proliferation, controls liver regeneration by repressing
p53/p21 activity [42]. These results coincide with our ﬁndings
presented in this report that δEF1 is a native repressor of p21 gene
in MDA-MB-231 breast cancer cells. Signiﬁcant down-regulation of
p21 transcription induced by δEF1 was observed within 3 h after δEF1
transfection, suggesting a direct mechanism is involved in this
regulation. In our study, the transfection of δEF1 did not appear to
completely shut down the p21 gene, but the level of p21 mRNAdropped swiftly to 60% in 3 h and maintained later on around 30% of
the control for up to 24 h. We thus speculate that the normal half life
of p21 mRNA is relatively short, perhaps less than 3 h. Regulation of
such a short-lived mRNA by δEF1 to cause signiﬁcant changes in
cellular functions indicated the p21/δEF1 balance plays a critical role
in the complex network that governs breast cancer cell function, and
likely tumor progression. We further found that δEF1 inhibited the
promoter activity of human p21 in a dose-dependent manner.
Depletion of δEF1 by RNA interference was sufﬁcient to allow a
native release of p21 expression. Importantly, we discovered that
deletion or mutation of the E2 box on p21 promoter remarkably
abolished the repressive effect of p21 transcription induced by δEF1.
δEF1 transfection in MDA-MB-231 cells resulted in a marked increase
of the binding afﬁnity of δEF1 to the endogenous p21 promoter,
indicating a signiﬁcant role of the E2 box element in mediating δEF1-
inhibited expression of p21. These data collectively supports the role
of δEF1 as a potential activator in the regulation of breast cancer
proliferation, which effect is mediated by modulating p21 expression.
We report here that there is an inverse correlation of δEF1 and p21
expressions in both breast cancer cell lines and in clinical tumor
specimens. We previously found that δEF1 is expressed at a higher
level in estrogen receptor (ER) negative breast cancer cells, whereas
BMP-6 expression is relatively higher in ER positive cells [26]. These
are consistent with the recent reports that in ER negative breast
cancer cell lines, ERα status is associated with low basal levels of p21
gene expression [43,44]. ERα itself is able to transactivate the p21
promoter and to exhibit a growth inhibitory activity in ER negative
cells [44]. Furthermore, the above results of concurrent increases in
BMP-6 and p21 in breast cancer cells suggest that BMP-6-induced
δEF1 inhibition is responsible, at least in part, for restoring p21
expression at both in vitro in breast carcinoma but also in vivo
situations. On the other hand, repression of δEF1 by BMP-6 has been
implied as a key event in mediating BMP-6-induced EMT inhibition in
breast cancer cells [26,39]. Meanwhile, BMP-6 addition to MDA-MB-
231 cells resulted in a signiﬁcant decreased cell numbers from G0/G1
into S phase, supporting a potential effect of BMP-6 in inducing cell
cycle arrest of breast cancer (un-published data). In the present
research, we found that artiﬁcial removal of δEF1 by RNA interference
resulted in an inhibition of G1-S transition of the cell cycle in MDA-
MB-231 cells, which effect is mediated via regulation of the p21 gene.
Taken together, our result supports a plausible mechanism that δEF1
and p21 are involved in BMP-6-regulated cell proliferation of breast
cancer. Importantly, factors that remove/decrease δEF1 level would
subsequently increase the expression of p21, thus inhibiting breast
cancer progression.
Our results present in this study also showed that, besides down-
regulating p21 expression, δEF1 concurrently up-regulated expres-
sions of CDK2 and CDK4 at both mRNA and protein levels, indicating
that δEF1 functions simultaneously as inhibitor and activator during
promoting breast cancer cell proliferation. Traditionally, δEF1 has
been identiﬁed as a widely expressed transcriptional repressor in
various cellular processes, via interactions with co-repressors or
competition with activators for DNA binding sites [15,18,19,23-
26,29,30]. However, several recent reports indicated that δEF1 can
also function as a transcriptional activator in regulating the speciﬁc
genes, including the vitamin D3 receptor and ovalbumin [45,46].
These are coincided with the ﬁnding from our group that δEF1
exhibits activation on microRNA-21 transcription during mediating
breast cancer EMT [47]. Collectively, we speculate a dual effect of δEF1
in control of breast cancer proliferation, by differentially regulating
p21, CDK2, and CDK4. However, the mechanism through which δEF1
activates CDK2 and/or CDK4 expression requires to be further
elucidated.
In conclusion, we have provided novel ﬁndings of a potential
mechanism for δEF1-regulated cell proliferation in breast cancer,
which effect is mediated through repressing p21 transcription by
312 F. Hu et al. / Biochimica et Biophysica Acta 1802 (2010) 301–312binding to the E2 box on its promoter. Moreover, δEF1 appeared to be
a key regulatory factor at the crossroad between proliferation and
differentiation, thus underscoring tumor progression and metastasis.
Together, δEF1 may represent a novel target molecule or therapeutic
approach for repression of systemic breast cancer progression.
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